Ralliant (NYSE:RAL) Receives “Buy” Rating from Truist Financial

Ralliant (NYSE:RAL)‘s stock had its “buy” rating reissued by analysts at Truist Financial in a research report issued on Friday,Benzinga reports. They presently have a $82.00 target price on the stock, up from their prior target price of $68.00. Truist Financial’s price objective would suggest a potential upside of 22.62% from the stock’s previous close.

Several other research firms have also commented on RAL. TD Cowen upped their price objective on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 20th. BMO Capital Markets started coverage on shares of Ralliant in a report on Monday, July 20th. They issued a “market perform” rating and a $78.00 price objective for the company. Oppenheimer lifted their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research note on Wednesday, May 27th. Finally, Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $74.40.

Ralliant Stock Performance

NYSE RAL opened at $66.88 on Friday. The firm has a market capitalization of $7.49 billion and a P/E ratio of -6.17. The stock has a 50-day simple moving average of $67.12 and a two-hundred day simple moving average of $54.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41.

Ralliant (NYSE:RAL) last issued its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S purchased a new position in shares of Ralliant during the fourth quarter worth about $25,000. Allworth Financial LP grew its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in Ralliant during the 4th quarter valued at about $26,000. Palisade Asset Management LLC acquired a new position in shares of Ralliant in the third quarter worth $26,000. Finally, Versant Capital Management Inc lifted its stake in shares of Ralliant by 230.1% during the second quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock valued at $44,000 after buying an additional 421 shares during the period.

More Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates: Ralliant reported adjusted EPS of $0.68, above the $0.63 consensus and slightly ahead of $0.67 a year earlier. Revenue reached approximately $568 million, up 13% year over year on both a reported and organic basis. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year guidance was raised: Ralliant now expects fiscal 2026 adjusted EPS of $2.76 to $2.90, compared with the $2.65 analyst consensus. Full-year revenue guidance was lifted to roughly $2.25 billion to $2.30 billion, also above the approximately $2.2 billion consensus. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Near-term outlook also topped expectations: Third-quarter guidance calls for adjusted EPS of $0.72 to $0.78 and revenue of $570 million to $590 million, above consensus estimates of $0.68 and $556.4 million, respectively.
• Positive Sentiment: Cost savings could support margins: Ralliant’s enterprise productivity program is targeting $50 million to $60 million in annualized run-rate savings by 2028, providing a potential longer-term earnings catalyst.
• Neutral Sentiment: Trading volatility increased: RAL was briefly halted under a limit-up/limit-down pause, indicating unusually rapid price movement following the results rather than a fundamental change in the company’s outlook.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.